A growing number of studies of novel targeted agents such as capmatinib and tepotinib for MET alterations have also used liquid biopsy as a diagnostic method for target identification in patients, leading to broader regulatory acceptance of plasma ctDNA testing as a companion diagnostic in patients with advanced NSCLC [59,60]. Here, MET is linked to non-small cell lung carcinoma.